SINTHealthcare · Medical DevicesThe 4 Wall Street analysts covering SINTX Technologies, Inc. hold a median 12-month price target of $9.25 — +504.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores SINTX Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SINT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +504.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Maxim Group | Reinstates | Buy | $6.00 |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 30 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 5 Feb 2024 | Maxim Group | Downgrade | Hold | — |
| 3 Apr 2023 | Maxim Group | Maintains | Buy | — |
| 15 Feb 2023 | Maxim Group | Maintains | Buy | — |
| 20 Jan 2023 | Maxim Group | Maintains | Buy | — |
| 3 Aug 2020 | Maxim Group | Upgrade | Buy | $4.50 |
| 12 Sept 2019 | Ascendiant Capital | Initiates | Buy | — |
| 11 Sept 2019 | Ascendiant Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SINT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 18% of US stocks
Cheaper than 45% of US stocks
Cheaper than 66% of US stocks
Higher than 96% of US stocks
Higher than 39% of US stocks
Higher than 23% of US stocks
Higher than 7% of US stocks
Higher than 85% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SINTX Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SINTX Technologies was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could potentially drive the stock higher in the near term.
Why it matters — A Zacks upgrade signals improving analyst sentiment toward SINTX's earnings outlook, which SINT watchers would view as a positive development.
SINTX Technologies announced it received written confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(b)(1), the minimum stockholders' equity requirement. Nasdaq based its determination on the company's Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, above the $2.5 million minimum, and confirmed that the previously disclosed deficiency matter is now closed.
Why it matters — Regaining compliance with Nasdaq's minimum stockholders' equity requirement resolves the previously disclosed deficiency and removes the associated risk of delisting for the company.
Sintx Technologies, Inc. released the prepared remarks transcript from its Q2 2026 earnings call via Seeking Alpha, providing management's official commentary on the company's second-quarter financial results.
Why it matters — For SINT watchers, the earnings call transcript offers direct insight into management's discussion of the company's latest quarterly performance and outlook.
SINTX Technologies issued a mid-year 2026 business update alongside its quarterly report for the quarter ended June 30, 2026. The company reported advancing commercialization of its FDA-cleared SiNAPTIC Foot & Ankle Implant System, expanding its commercial distribution network, raising additional capital, investing in advanced manufacturing, and broadening its silicon nitride technology platform across healthcare and industrial markets.
Why it matters — The update offers SINT watchers an overview of the company's first-half 2026 execution on commercialization, manufacturing investment, and expansion of its silicon nitride platform across multiple markets.
SINTX Technologies announced it will release its second quarter 2026 financial results after market close on August 11, 2026, and will host a conference call and webcast at 4:30 p.m. that day.
Why it matters — The announcement provides the date and time for SINTX's quarterly earnings report, allowing investors and analysts to prepare for the release and subsequent conference call.
The 4 Wall Street analysts covering SINTX Technologies, Inc. have a median 12-month price target of $9.25, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering SINTX Technologies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SINTX Technologies, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, SINTX Technologies, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +504.6% from the last close, and Ticker Nerd's factor model ranks SINTX Technologies, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SINTX Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SINT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
SINTX Technologies, Inc. returned -53.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sintx Technologies Inc. is an advanced ceramics company specializing in the research, development, and commercialization of silicon nitride-based medical devices and biomaterials.
The most recent item we track (Zacks Investment Research, 19 Aug 2026): "SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade". SINTX Technologies was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could potentially drive the stock higher in the near term.
Sintx Technologies Inc. is an advanced ceramics company specializing in the research, development, and commercialization of silicon nitride-based medical devices and biomaterials. It manufactures solid and porous silicon nitride products, silicon nitride powder, coatings, and composite materials including polyether ether ketone and polyetherketoneketone for biomedical, technical, and antipathogenic applications. The company offers innovative solutions such as the FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and OsseoSculpt biologic, which feature pro-osteogenic, bacteriostatic, and enhanced imaging properties. Sintx Technologies Inc. also develops antipathogenic fibrous materials and fabrics for medical textiles, wound dressings, filtration, PPE, and high-touch surfaces, supported by composition and method patents. Recent advancements include the SiN/PEEK compound produced via partnerships for AI-assisted, 3D-printed patient-specific implants targeting orthopedic, spine, and reconstructive surgery markets. Founded in 1996 and headquartered in Salt Lake City, Utah, Sintx Technologies Inc. focuses on infection-resistant devices, polymer composites, and licensing opportunities in the medical device sector.
CEO Mr. Eric K. Olson · 32 employees · United States · https://www.sintx.com